102908 Federal Register / Vol. 89, No. 243 / Wednesday, December 18, 2024 / Notices 

1See 12 CFR 217.402, 217.404. 2Method 2 uses similar inputs to those used in 

method 1 but replaces the substitutability category 

with a measure of a firm’s use of short-term 

wholesale funding. In addition, method 2 is 

calibrated differently from method 1. See 12 CFR 

217.405. 

unit. Information submitted on the 

substances within a category should be 

reported for each individual chemical 

structure, to the extent possible (i.e., 

known or reasonably ascertainable). If 

the chemical identity of some of the 

individual chemical structures are not 

known or reasonably ascertainable by 

the commenter, the information 

associated with those chemical 

substances may be reported as a group 

of chemical structures (i.e., isomeric 

mixture) or as the chemical category: 

• 1-Hexadecanol, CASRN 36653–82– 

4; 

• 2-Ethylhexyl 2,3,4,5- 

tetrabromobenzoate (TBB), CASRN 

183658–27–7; 

• Bis(2-Ethylhexyl)-3,4,5,6- 

Tetrabromophthalate (TBPH), CASRN 

26040–51–7; 

• Bisphenol A, CASRN 80–05–7; 

• Creosote, CASRN 8001–58–9; 

• Di-n-octyl phthalate (DnOP), 

CASRN 117–84–0; 

• N-Nitroso-diphenylamine, CASRN 

86–30–6; 

• P,P′- 

Oxybis(benzenesulfonylhydrazide), 

CASRN 80–51–3; 

• Tribromomethane, CASRN 75–25– 

2; 

• Triglycidyl isocyanurate, CASRN 

2451–62–9; 

• M-Xylene, CASRN 108–38–3; 

• O-Xylene, CASRN 95–47–6; 

• P-Xylene, CASRN 106–42–3; 

• Antimony and Antimony 

Compounds, Category; 

• Arsenic and Arsenic Compounds, 

Category; 

• Cobalt and Cobalt Compounds, 

Category; 

• Lead and Lead Compounds, 

Category; 

• Long-chain chlorinated paraffins 

(C18-20), Category; 

• Medium-chain chlorinated paraffins 

(C14-17), Category; 

• Bisphenol S, CASRN 80–09–1; 

• Hydrogen Fluoride, CASRN 7664– 

39–3; 

• N-(1,3-Dimethylbutyl)-N′-phenyl-pphenylenediamine (6PPD), CASRN 793– 

24–8. 

C. How will confidential business 

information be protected? 

A person seeking to protect from 

disclosure as ‘‘confidential business 

information’’ any information that 

person submits under TSCA must assert 

and substantiate a claim for protection 

from disclosure concurrent with 

submission of the information in 

accordance with the requirements of 

TSCA section 14 and 40 CFR 703, with 

limited exceptions provided in the 

statute. TSCA section 14(b) limits 

confidentiality protections for health 

and safety studies and information from 

such studies, however, and while EPA 

considers confidential business 

information when conducting its review 

under 40 CFR 702.9(a), the Agency 

encourages submitters to minimize 

claims for protection from disclosure 

wherever possible to maximize 

transparency in EPA’s screening review. 

More information on asserting and 

submitting confidential business 

information claims under TSCA can be 

found at 40 CFR 703 and https://

www.epa.gov/tsca-cbi. 

Authority: 15 U.S.C. 2601 et seq. 

Dated: December 12, 2024. 

Michal Freedhoff, 

Assistant Administrator, Office of Chemical 

Safety and Pollution Prevention. 

[FR Doc. 2024–29829 Filed 12–17–24; 8:45 am] 

BILLING CODE 6560–50–P 

FEDERAL ELECTION COMMISSION 

Sunshine Act Meetings 

FEDERAL REGISTER CITATION NOTICE OF

PREVIOUS ANNOUNCEMENT: 89 FR 89012. 

PREVIOUSLY ANNOUNCED TIME AND DATE OF

THE MEETING: Thursday, November 14, 

2024 at 11:00 a.m., Hybrid Meeting: 

1050 First Street NE, Washington, DC 

(12th Floor) and virtual. 

CHANGE IN THE MEETING: The November 

14, 2024 Open Meeting was canceled. 

CONTACT PERSON FOR MORE INFORMATION: 

Judith Ingram, Press Officer. Telephone: 

(202) 694–1220. 

(Authority: Government in the Sunshine Act, 

5 U.S.C. 552b) 

Laura E. Sinram, 

Secretary and Clerk of the Commission. 

[FR Doc. 2024–30107 Filed 12–16–24; 11:15 am] 

BILLING CODE 6715–01–P 

FEDERAL RESERVE SYSTEM 

[Docket No. OP–1863] 

Regulation Q; Regulatory Capital Rule: 

Risk-Based Capital Surcharges for 

Global Systemically Important Bank 

Holding Companies 

AGENCY: Board of Governors of the 

Federal Reserve System (Board). 

ACTION: Notice. 

SUMMARY: The Board is providing notice 

of the 2024 aggregate global indicator 

amounts, as required under the Board’s 

rule regarding risk-based capital 

surcharges for global systemically 

important bank holding companies. 

DATES: December 18, 2024. 

FOR FURTHER INFORMATION CONTACT: 

Anna Lee Hewko, Associate Director, 

(202) 250–1577, Brian Chernoff, 

Manager, (202) 731–8914, Alexander 

Jiron, Senior Financial Institution Policy 

Analyst II, (202) 450–7350, or Aakash 

Jani, Senior Financial Institution Policy 

Analyst I, (202) 941–8305, Division of 

Supervision and Regulation; or Jay 

Schwarz, Deputy Associate General 

Counsel, (202) 452–2970, Mark Buresh, 

Senior Special Counsel, (202) 499–0261, 

Jonah Kind, Senior Counsel, (202) 309– 

5287, or David Imhoff, Senior Attorney 

(202) 834–3222, Legal Division. Board of 

Governors of the Federal Reserve 

System, 20th and C NW, Washington, 

DC 20551. For the hearing impaired and 

users of Telecommunications Device for 

the Deaf (TDD) and TTY–TRS, please 

call 711 from any telephone, anywhere 

in the United States. 

SUPPLEMENTARY INFORMATION: The 

Board’s framework for determining riskbased capital surcharges for global 

systemically important bank holding 

companies (GSIB surcharge rule) 

establishes a methodology to identify 

global systemically important bank 

holding companies (GSIBs) in the 

United States based on indicators that 

are correlated with systemic 

importance.1 Under the GSIB surcharge 

rule, a firm must calculate its GSIB 

score using a specific formula (method 

1). Method 1 uses five equally weighted 

categories that are correlated with 

systemic importance—size, 

interconnectedness, cross-jurisdictional 

activity, substitutability, and 

complexity—and subdivided into 

twelve systemic indicators. 

A firm divides its own measure of 

each systemic indicator by an aggregate 

global indicator amount. A firm’s 

method 1 score is the sum of its 

weighted systemic indicator scores 

expressed in basis points. A firm that 

calculates a method 1 score of 130 basis 

points or more is identified as a GSIB 

under the GSIB surcharge rule. The 

GSIB surcharge for a firm is the higher 

of the GSIB surcharge determined under 

method 1 and a second method, method 

2, which is calculated based on 

measures of size, interconnectedness, 

cross-jurisdictional activity, complexity, 

and the firm’s reliance on short-term 

wholesale funding.2

The aggregate global indicator 

amounts used in the score calculation 


khammond on DSK9W7S144PROD with NOTICES
Federal Register / Vol. 89, No. 243 / Wednesday, December 18, 2024 / Notices 102909 

3The data used by the Board are available on the 

BCBS website at https://www.bis.org/bcbs/gsib/ 

denominators.htm. 

4 12 CFR 217.404(b)(1)(i)(B); see also 80 FR 49082, 

49086–87 (August 14, 2015). In addition, the Board 

maintains the GSIB Framework Denominators on its 

website, available at https:// 

www.federalreserve.gov/supervisionreg/basel/ 

denominators.htm. 

5Foreign exchange rates provided by the BCBS. 

Available at https://www.bis.org/bcbs/gsib/ 

reporting_instructions.htm. 

under method 1 are based on data 

collected by the Basel Committee on 

Banking Supervision (BCBS). The BCBS 

amounts are determined based on the 

sum of the systemic indicator amounts 

as reported by the 75 largest U.S. and 

foreign banking organizations as 

measured by the BCBS, and any other 

banking organization that the BCBS 

includes in its sample total for that year. 

The BCBS publicly releases these 

amounts, denominated in euros, each 

year.3 Pursuant to the GSIB surcharge 

rule, the Board publishes the aggregate 

global indicator amounts each year as 

denominated in U.S. dollars using the 

euro-dollar exchange rate provided by 

the BCBS.4 Specifically, to determine 

the 2024 aggregate global indicator 

amounts, the Board uses the year-end 

2023 euro-denominated indicator 

amounts published by the BCBS and 

multiplies each of the eurodenominated indicator amounts by 

1.105, the euro to U.S. dollar spot 

exchange rate on December 31, 2023.5

The aggregate global indicator 

amounts expressed in U.S. dollars for 

purposes of the 2024 method 1 score 

calculation under § 217.404(b)(1)(i)(B) of 

the GSIB surcharge rule are: 

AGGREGATE GLOBAL INDICATOR AMOUNTS IN U.S. DOLLARS (USD) FOR 2024 

Category Systemic indicator 

Aggregate global 

indicator amount 

(in USD) 

Size ........................................................................ Total exposures ............................................................................... $115,205,051,188,518 

Interconnectedness ............................................... Intra-financial system assets ........................................................... 11,253,226,663,114 

Intra-financial system liabilities ........................................................ 11,388,383,441,235 

Securities outstanding ..................................................................... 19,247,590,871,111 

Substitutability ........................................................ Payments activity ............................................................................ 3,527,103,136,881,927 

Assets under custody ...................................................................... 219,479,268,261,988 

Underwritten transactions in debt and equity markets ................... 7,962,804,019,185 

Complexity ............................................................. Notional amount of over-the-counter (OTC) derivatives ................. 733,514,990,056,729 

Trading and available-for-sale (AFS) securities .............................. 4,278,831,961,372 

Level 3 assets ................................................................................. 803,127,442,989 

Cross-jurisdictional activity .................................... Cross-jurisdictional claims ............................................................... 28,416,427,492,687 

Cross-jurisdictional liabilities ........................................................... 23,524,643,383,930 

Authority: 12 U.S.C. 248(a), 321–338a, 

481–486, 1462a, 1467a, 1818, 1828, 

1831n, 1831o, 1831p–l, 1831w, 1835, 

1844(b), 1851, 3904, 3906–3909, 4808, 

5365, 5368, 5371. 

By order of the Board of Governors of the 

Federal Reserve System, acting through the 

Director of Supervision and Regulation under 

delegated authority. 

Ann E. Misback, 

Secretary of the Board. 

[FR Doc. 2024–29981 Filed 12–17–24; 8:45 am] 

BILLING CODE 6210–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Notice of Meetings 

AGENCY: Agency for Healthcare Research 

and Quality (AHRQ), Department of 

Health and Human Services (HHS). 

ACTION: Notice of five AHRQ 

subcommittee meetings. 

SUMMARY: The subcommittees listed 

below are part of AHRQ’s Health 

Services Research Initial Review Group 

(IRG) Committee. Grant applications are 

to be reviewed and discussed at these 

meetings. Each subcommittee meeting 

will be closed to the public. 

DATES: See below for dates of meetings: 

1. Healthcare Safety and Quality 

Improvement Research (HSQR). 

Date: February 5–6, 2025. 

2. Healthcare Effectiveness and 

Outcomes Research (HEOR). 

Date: February 5–6, 2025. 

3. Health System and Value Research 

(HSVR). 

Date: February 13–14, 2025. 

4. Healthcare Research Training 

(HCRT). 

Date: February 27–28, 2025. 

5. Healthcare Information Technology 

Research (HITR). 

Date: February 27–28, 2025. 

ADDRESSES: Agency for Healthcare 

Research and Quality (Virtual Review), 

5600 Fishers Lane, Rockville, Maryland 

20857. 

FOR FURTHER INFORMATION CONTACT: (to 

obtain a roster of members, agenda or 

minutes of the non-confidential portions 

of the meetings.)Jenny Griffith, 

Committee Management Officer, 

Division of Policy, Coordination and 

Analysis, Office of Extramural Research 

Education and Priority Populations, 

Agency for Healthcare Research and 

Quality (AHRQ), 5600 Fishers Lane, 

Rockville, Maryland 20857, telephone 

(301) 427–1557. 

SUPPLEMENTARY INFORMATION: In 

accordance with the Federal Advisory 

Committee Act, 5 U.S.C. 1009(a)(2), 

AHRQ announces meetings of the 

above-listed scientific peer review 

groups, which are subcommittees of 

AHRQ’s Health Services Research Initial 

Review Group Committee. The 

subcommittee meetings will be closed to 

the public in accordance with the 

provisions set forth in 5 U.S.C. 1009(d), 

5 U.S.C. 552b(c)(4), and 5 U.S.C. 

552b(c)(6). The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Agenda items for these meetings are 

subject to change as priorities dictate. 

Dated: December 12, 2024. 

Marquita Cullom, 

Associate Director. 

[FR Doc. 2024–29969 Filed 12–17–24; 8:45 am] 

BILLING CODE 4160–90–P 


khammond on DSK9W7S144PROD with NOTICES